KI
PCRX icon

Kula Investments’s Pacira BioSciences PCRX Stock Holding History

Kula Investments’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$1.29M Buy
+31,665
New +$1.26M 0.32% 65

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Kula Investments's PCRX Position: Q1 2023 in Review

Kula Investments opened a new position in Pacira BioSciences (PCRX) in Q1 2023: 31,665 shares worth $1.29M. The stake represents 0.32% of the portfolio and ranks #65 among its holdings.

267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

  • Kula Investments held 31,665 shares of Pacira BioSciences worth $1.29M as of Q1 2023.
  • Pacira BioSciences was a new Kula Investments position in Q1 2023.
  • Pacira BioSciences made up 0.32% of Kula Investments's portfolio in Q1 2023, its #65 holding.
  • 267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Kula Investments's 13F filing for Q1 2023, filed 15 May 2023.